{"id":2306,"date":"2020-07-20T08:42:39","date_gmt":"2020-07-20T06:42:39","guid":{"rendered":"https:\/\/cendoc.h12o.es\/blog\/?p=2306"},"modified":"2020-07-20T08:42:39","modified_gmt":"2020-07-20T06:42:39","slug":"tocilizumab-neumonia-grave-por-covid-19-y-h12o","status":"publish","type":"post","link":"https:\/\/cendoc.h12o.es\/blog\/2020\/07\/20\/tocilizumab-neumonia-grave-por-covid-19-y-h12o\/","title":{"rendered":"Tocilizumab, neumon\u00eda grave por COVID-19 y H12O"},"content":{"rendered":"<p>Profesionales de 11 servicios del Hospital 12 de Octubre (Medicina Interna, Cardiolog\u00eda, Farmacia Hospitalaria, Medicina Intensiva, Neumolog\u00eda, Oncolog\u00eda M\u00e9dica, Inmunolog\u00eda, Hematolog\u00eda, Urgencias, Reumatolog\u00eda y Nefrolog\u00eda) han analizado el uso del tocilizumab en pacientes adultos con neumon\u00eda grave por COVID-19 en una cohorte de 88 pacientes.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"  wp-image-3871 alignright\" src=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=213&amp;h=142\" sizes=\"(max-width: 213px) 100vw, 213px\" srcset=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=213&amp;h=142 213w, https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=150&amp;h=100 150w, https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg 275w\" alt=\"logo12\" width=\"213\" height=\"142\" data-attachment-id=\"3871\" data-permalink=\"https:\/\/coronavirusbiblioh12o.wordpress.com\/2020\/05\/06\/7-mas-del-h12o\/logo12\/\" data-orig-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg\" data-orig-size=\"275,183\" data-comments-opened=\"1\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"logo12\" data-image-description=\"\" data-medium-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" data-large-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" \/><\/p>\n<p>Ante la liberaci\u00f3n masiva de citoquinas en pacientes con COVID-19 se propone el uso de tocilizumab en la fase hiperinflamatoria, aunque la evidencia cient\u00edfica sobre su eficacia hasta el momento es limitada. El trabajo analiza la evoluci\u00f3n de los pacientes durante 14 d\u00edas, desde que recibieron su primera dosis de TCZ, a partir de una escala de 6 puntos. Los autores concluyen que en este estudio observacional realizado en un \u00fanico centro (el Hospital 12 de Octubre), el tratamiento con tocilizumab parece \u00fatil y seguro como terapia inmunomoduladora frente a neumon\u00eda grave causada por COVID-19.<\/p>\n<p>El art\u00edculos ha sido publicado en el <em>Journal of Medical Virology<\/em> y lleva por t\u00edtulo: \u201c<a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jmv.26308\" target=\"_blank\" rel=\"noopener\">Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study<\/a>\u201d.<\/p>\n<p><em>Equipo Biblioteca H12O<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Profesionales de 11 servicios del Hospital 12 de Octubre (Medicina Interna, Cardiolog\u00eda, Farmacia Hospitalaria, Medicina Intensiva, Neumolog\u00eda, Oncolog\u00eda M\u00e9dica, Inmunolog\u00eda, Hematolog\u00eda, Urgencias, Reumatolog\u00eda y Nefrolog\u00eda) han analizado el uso del tocilizumab en pacientes adultos con neumon\u00eda grave por COVID-19 en una cohorte de 88 pacientes. Ante la liberaci\u00f3n masiva de \u2026<\/p>\n<p class=\"continue-reading-button\"> <a class=\"continue-reading-link\" href=\"https:\/\/cendoc.h12o.es\/blog\/2020\/07\/20\/tocilizumab-neumonia-grave-por-covid-19-y-h12o\/\">Continuar leyendo<i class=\"crycon-right-dir\"><\/i><\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false},"version":2}},"categories":[4,64,46],"tags":[14,65,47],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p3G9TJ-Bc","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2306"}],"collection":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/comments?post=2306"}],"version-history":[{"count":1,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2306\/revisions"}],"predecessor-version":[{"id":2307,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2306\/revisions\/2307"}],"wp:attachment":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/media?parent=2306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/categories?post=2306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/tags?post=2306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}